Enovis Corp's shares slipped to a 52‑week low of US$19.12 on September 3, 2026, following the release of its second‑quarter 2026 results and news of a major acquisition.
For the quarter, the company posted adjusted earnings of US$0.90 per share, topping the Wall Street consensus estimate of US$0.85. Total revenue came in at US$582.78 million, matching analysts' expectations.
Enovis also announced the acquisition of French surgical‑robotics firm eCential Robotics. The deal is valued at approximately €176 million, with an enterprise value of €155 million and potential milestone payments of up to €35 million.
In response, Citizens lowered its price target for Enovis from US$55 to US$47, while BMO Capital reduced its target from US$30 to US$27; both firms kept an outperform rating. The stock has fallen 18.65% over the past week, 39.14% over the last year, and was down 3.96% on the day of reporting.
InvestingPro notes that the Relative Strength Index places the stock in oversold territory. Market participants expressed concern over the company's cautious short‑term outlook, persistent cost pressures and anticipated margin strain from the acquisition, though analysts still project a return to profitability later in the year.
